Biosimilars Regulations in the US Market: Where Do We Go From Here?

Biosimilars Regulations in the US Market: Where Do We Go From Here?
Thomas Sullivan, President, Rockpointe, takes a look at 2015-2016 at FDA and around the world, differences between EMA and FDA biosimilars regulations, FDA developments, CMS JCODES, state substitution laws, and the future of biosimilars.

Please note: That all fields marked with an asterisk (*) are required.